- Home
- ABEO
as 10-15-2025 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 289.2M | IPO Year: | 1980 |
| Target Price: | $18.17 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.93 - $7.54 | Next Earning Date: | 11-13-2025 |
| Revenue: | $400,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 324.71% |
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | ABEO | Chief Executive Officer | Sep 30 '25 | Sell | $5.24 | 25,000 | $130,930.00 | 1,190,067 | |
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Sep 29 '25 | Sell | $5.39 | 9,366 | $50,515.52 | 350,763 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Sep 29 '25 | Sell | $5.39 | 9,035 | $48,730.27 | 453,631 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Sep 29 '25 | Sell | $5.39 | 19,274 | $103,954.32 | 1,190,067 | |
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Sep 22 '25 | Sell | $5.43 | 688 | $3,735.84 | 350,763 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Aug 15 '25 | Sell | $7.36 | 15,000 | $110,358.00 | 453,631 | |
| Crombez Eric | ABEO | N/A | Aug 14 '25 | Sell | $6.93 | 4,718 | $32,683.00 | 42,427 |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Abeona's Gene Therapy for Rare Eye Disease Selected for FDA Pilot Program
GlobeNewswire
3 days ago
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
Simply Wall St.
6 days ago
3 Top Growth Stocks Insiders Are Eager To Hold
GlobeNewswire
8 days ago
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
Simply Wall St.
3 months ago
Abeona Therapeutics Inc. (NASDAQ:ABEO) About To Shift From Loss To Profit
GlobeNewswire
3 months ago
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
PR Newswire
3 months ago
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
GlobeNewswire
4 months ago
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.